What the trials can tell you

For a semaglutide specialist conversation, it helps to ask which study relates to the health problem being discussed. A weight result and a heart result may come from quite different groups. Read about the people who took part, called the study population, before treating a percentage as a personal expectation.

• Who was allowed into the study?
• What was the comparison group given?
• What outcome did researchers measure?
• What support accompanied the medicine?
• What limits did the researchers report?

The weight result included ongoing support

For STEP 1, researchers recruited adults with obesity but without diabetes. It also included adults with overweight and a related health problem. Both groups had lifestyle support: regular visits and counseling about everyday habits. Ask what help with food choices and physical activity would accompany your own care. After 68 weeks, the drug group’s average weight loss was 14.9%; the placebo group’s was 2.4%.

The study had regular visits and lifestyle counseling, and Novo Nordisk funded it. The average does not mean every participant lost that amount.

• Ask what support would accompany your own care.
• Ask which outcome matters beyond a headline weight figure.
• Ask when the treatment plan would be reviewed.

This result supports a discussion about treatment. It cannot tell a reader what to take or how much to take.

Stopping was studied too

A follow-up of STEP 1 participants found that, a year after treatment stopped, the group previously taking semaglutide had regained about two-thirds of its earlier weight loss.

That finding came from a smaller follow-up group. It is not an instruction that everyone must continue indefinitely.

Bring the longer view into the discussion before starting a paid care plan. Ask how your clinician, the doctor or other licensed health professional providing care, would review benefit, burden, affordability and a possible change of approach. Those are fair questions even when the immediate conversation is about getting started.

• How will we discuss whether continuing is worthwhile?
• What happens if the cost becomes hard to manage?
• Who would help plan a change in treatment?

Heart results came from a particular group

SELECT enrolled adults with established heart disease and excess weight who did not have diabetes. SELECT tracked a combined outcome: cardiovascular death, nonfatal stroke or nonfatal heart attack. Cardiovascular means related to the heart and blood vessels. Over about 40 months, the trial recorded this outcome in 6.5% of the medicine group and 8.0% of the placebo group.

The groups differed by 1.5 percentage points. The trial’s reported relative reduction was about 20%: the medicine group’s risk was about a fifth lower compared with the placebo group’s risk. This compares the groups; it cannot tell you your own chance of a heart problem.

In the same trial, reported health problems led 16.6% of people on semaglutide to stop treatment permanently, compared with 8.2% on placebo.

• Ask whether the trial population resembles the reason for your care.
• Read the 6.5% and 8.0% event rates first: those are the percentages of people in each group who had an event. Then read the about 20% comparison between groups.
• Ask how often people could stay with treatment as well as what it achieved.

Do not give a study a bigger answer

For the liver disease called MASH, semaglutide trial results showed improvements in liver samples. Those biopsy findings, from samples of liver tissue, do not yet establish prevention of liver failure or death.

A safety report is a different kind of evidence. FDA says a report alone cannot prove a medicine caused the event or establish how often it happens.

When an offer gives a bold result, ask for the study and the measured outcome. Open the sources below for the underlying papers. If the headline leaves out the population, the comparison or the limits, take those missing pieces to the care conversation.